207 related articles for article (PubMed ID: 31454149)
1. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C
J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149
[TBL] [Abstract][Full Text] [Related]
2. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
[TBL] [Abstract][Full Text] [Related]
3. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
4. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
[TBL] [Abstract][Full Text] [Related]
5. DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
Li Y; Zhou D; Xu S; Rao M; Zhang Z; Wu L; Zhang C; Lin N
Cancer Biol Med; 2020 May; 17(2):387-400. PubMed ID: 32587776
[No Abstract] [Full Text] [Related]
6. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
Ku BM; Choi MK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
PLoS One; 2018; 13(4):e0194730. PubMed ID: 29641535
[TBL] [Abstract][Full Text] [Related]
7. AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.
Wu S; Zhu L; Tu L; Chen S; Huang H; Zhang J; Ma S; Zhang S
Radiat Res; 2018 Mar; 189(3):283-291. PubMed ID: 29332537
[TBL] [Abstract][Full Text] [Related]
8. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
9. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
[TBL] [Abstract][Full Text] [Related]
11. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
12. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
[TBL] [Abstract][Full Text] [Related]
13. AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.
Zhang Z; Zhang M; Liu H; Yin W
J Cell Biochem; 2019 Jan; 120(1):756-767. PubMed ID: 30145802
[TBL] [Abstract][Full Text] [Related]
14. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
[TBL] [Abstract][Full Text] [Related]
15. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
16. IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer.
Tang X; Mu J; Ma L; Tan Q; Wang J; Tan J; Zhang S
Biochem Biophys Res Commun; 2021 Sep; 571():38-45. PubMed ID: 34303194
[TBL] [Abstract][Full Text] [Related]
17. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
19. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
